Deregulation of Aiolos expression in chronic lymphocytic leukemia is associated with epigenetic modifications

Billot, Katy; Sœur, Jérémie; Chéreau, Fanny; Arrouss, Issam; Merle-Béral, Hélène; Huang, Meng‐Er; Mazier, Dominique; Baud, Véronique; Rebollo, Angelita

doi:10.1182/blood-2010-09-307140

Cited by 39 publications

(36 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…p65/RelA binding to the chromatin is more important in low-grade MDS where the CpG methylation is low compared with high-grade MDS in which the level of DNA methylation is high. Such an epigenetic regulation of NF-kB-dependent transcription has been reported for AIOLOS gene in chronic lymphocytic leukemia (40).…”

Section: Discussionsupporting

confidence: 67%

Epigenetic Control of NF-κB-Dependent FAS Gene Transcription during Progression of Myelodysplastic Syndromes

Ettou

Humbrecht

Benet

et al. 2013

Molecular Cancer Research

Self Cite

View full text Add to dashboard Cite

The death domain containing TNF receptor 6 (CD95/Fas) is a direct target for the NF-kB transcription factor and is repressed in solid tumors such as colon carcinomas. Previously, we reported that the Fas death receptor, while overexpressed in low-risk myelodysplastic syndromes (MDS), becomes undetectable on CD34 þ progenitors when the disease progresses to secondary acute myeloid leukemia (AML). This study determined the interplay between NF-kB and Fas during MDS progression. We first observed that Fas was induced by TNF-a in the HL60 cell line. In these cells, p65 (RELA) was associated with the FAS promoter, and inhibition of the NF-kB pathway by an IKKa inhibitor (BAY11-7082) or lentiviral expression of a nondegradable mutant of IkBa (IkSR)

show abstract

Section: Discussionsupporting

confidence: 67%

Epigenetic Control of NF-κB-Dependent FAS Gene Transcription during Progression of Myelodysplastic Syndromes

Ettou

Humbrecht

Benet

et al. 2013

Molecular Cancer Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…This binding prevents the CRBN auto-ubiquitination and also promotes the recognition and degradation of the transcription factors Ikaros and Aiolos. Ikaros and Aiolos are critical for B and T cell biology [78][79][80].…”

Section: Immunomodulatory Drugsmentioning

confidence: 99%

Magic pills: new oral drugs to treat chronic lymphocytic leukemia

Vitale

Griggio

Todaro

et al. 2017

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Introduction: A deeper understanding of chronic lymphocytic leukemia (CLL) biology has led to the identification of new promising therapeutic targets. Different classes of molecules are currently under investigation and novel oral drugs have recently been approved or are in a late stage of clinical development. Areas covered: We present biological data illustrating the heterogeneous mechanisms of action of new oral drugs in CLL. Moreover, we provide clinical data from phase I to III studies, and discuss efficacy and side effects profile of these new therapies. Data are derived from peer-reviewed articles indexed in PubMed and from abstracts presented at major international meetings. Expert opinion: Novel oral drugs represent a valuable alternative to chemo-immunotherapy for patients with CLL, especially when high-risk disease features are present and when age or comorbidities preclude the use of standard treatments. Based on data from ongoing clinical trials, the indications of already approved agents will most likely be expanded and new options will soon be available. Moreover, treatment combinations will broaden the therapeutic armamentarium of physicians treating CLL. The availability of multiple choices is of benefit for patients with CLL, but also represents a challenge for the need of choosing the right drug for each patient. ARTICLE HISTORY

show abstract

“…In this regard, epigenetically up-regulated Aiolos, a member of Ikaros family of transcriptional factors involved in lymphocyte differentiation and lineage specification (rev. Mandel and Grosschedl, 2010;John and Ward, 2011), whose transcriptional regulation is under NF-B control, may contribute to the resistance of CLL cells to activate apoptotic cell death (Billot et al 2011). …”

Section: Epigenetic Control and Cll Cells Resistance To Dna Damage-inmentioning

confidence: 99%

DNA Damage Response/Signaling and Genome (In)Stability as the New Reliable Biological Parameters Defining Clinical Feature of CLL

Delić¹,

Marteau²,

Maloum³

et al. 2012

Chronic Lymphocytic Leukemia

View full text Add to dashboard Cite

Deregulation of Aiolos expression in chronic lymphocytic leukemia is associated with epigenetic modifications

Cited by 39 publications

References 51 publications

Epigenetic Control of NF-κB-Dependent FAS Gene Transcription during Progression of Myelodysplastic Syndromes

Epigenetic Control of NF-κB-Dependent FAS Gene Transcription during Progression of Myelodysplastic Syndromes

Magic pills: new oral drugs to treat chronic lymphocytic leukemia

DNA Damage Response/Signaling and Genome (In)Stability as the New Reliable Biological Parameters Defining Clinical Feature of CLL

Contact Info

Product

Resources

About